News | March 11, 2024
Briefs: Zydus Lifesciences and Rainbow Children's Medicare
Zydus Lifesciences receives EIR report from USFDA for API Ahmedabad facility
Zydus Lifesciences receives EIR report from USFDA for API Ahmedabad facility
The product combines proven efficacy of Doxylamine succinate 20 mg and Pyridoxine hydrochloride 20 mg in an Extended Release formulation
ANVISA issues CGMP to Concord Biotech’s Unit I
Sadhana Nitro Chem's plant is the second plant in the world to manufacture pAP from Nitrobenzene
Acquisition of exclusive commercialization rights for European markets
Cipla completes transfer of Generics Business Undertaking
The agreement licenses the company to launch in the United States, in February 2025, once approved by the U.S. FDA
Eugia Pharma Specialities restarts production at terminally sterilized product lines
_in_Mizushima,_Japan_256_384.jpg)
Contributing to lower risk of potentially carcinogenic nitrosamine impurities in pharmaceuticals
The U.S. FDA recently approved Xolair as the first and only medicine for children and adults with one or more food allergies
Subscribe To Our Newsletter & Stay Updated
